ArticleMikrochimica acta2025
Gold-silica hybrid nanolabels decorated with recognition and signaling bioreagents for enhanced electrochemical immunodetection of chemokine ligand-12 in colorectal cancer early diagnosis and monitoring.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Colorectal Cancer: Epidemiology, Gender and Sex Differences in Biomarkers and Their Perspectives for Novel Biosensing Detection Methods.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The use of gold-silica nanoconjugates (Au@SiO₂NCs) decorated with biotinylated detection antibodies (b-dAb) and horseradish peroxidase (HRP) is reported for the improved electrochemical immunosensing of chemokine ligand-12 (CXCL12), a relevant chemokine implicated in colorectal cancer (CRC) progression. Implemented on an amperometric sandwich immunoplatform the resulting nanobioconjugates provided significant signal amplification which is attributed to the high enzyme loading capacity and improved antibody orientation. The role played by each of the nanomaterials forming the nanohybrid was evaluated. Under optimized conditions, the developed immunoplatform exhibited a linear response ranging from 72 to 1000 pg mL
Indexed as
Identifiers
40425890What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.